Applies to sofosbuvir: oral tablet
As well as its needed effects, sofosbuvir may cause unwanted side effects that require medical attention. 
If any of the following side effects occur while taking sofosbuvir, check with your doctor immediately:
Some sofosbuvir side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:


Applies to sofosbuvir: oral tablet
This drug should be used with ribavirin or peginterferon alfa/ribavirin.  The manufacturer product information for these agents should be consulted for side effects.The most common side effects reported with sofosbuvir and ribavirin therapy were fatigue and headache.  The most common side effects reported with sofosbuvir, peginterferon alfa, and ribavirin therapy were fatigue, headache, nausea, insomnia, and anemia.  Therapy was permanently discontinued due to side effects in 1.4% to 4% of subjects using placebo, 0.5% to 1% of subjects using sofosbuvir and ribavirin for 12 weeks, less than 1% of subjects using sofosbuvir and ribavirin for 24 weeks, 11.1% of subjects using peginterferon alfa and ribavirin for 24 weeks, and 2.4% of subjects using sofosbuvir, peginterferon alfa, and ribavirin for 12 weeks.[Ref]
Very common (10% or more): Fatigue (up to 59%), asthenia (up to 21%), pyrexia (up to 18%), chills (up to 17%), influenza-like illness (up to 16%), painCommon (1% to 10%): Chest pain[Ref]
Very common (10% or more): Headache (up to 36%), dizzinessCommon (1% to 10%): Disturbance in attention, migraine, memory impairment[Ref]
Increased lipase (greater than 3 times upper limit of normal [ULN]) was reported in up to 2% of patients.  Lipase elevation was isolated and asymptomatic.[Ref]
Very common (10% or more): Nausea (up to 34%), diarrhea (up to 12%), vomitingCommon (1% to 10%): Increased lipase, abdominal discomfort, constipation, dyspepsia, dry mouth, gastroesophageal reflux[Ref]
Very common (10% or more): Pruritus (up to 27%), rash (18%)Common (1% to 10%): Alopecia, dry skin[Ref]
Very common (10% or more): Insomnia (up to 25%), irritability (up to 13%)Common (1% to 10%): Depression, anxiety, agitationUncommon (0.1% to 1%): Severe depression (including suicidal ideation, suicide)[Ref]
Severe depression was reported, particularly in patients with history of psychiatric illness.[Ref]
Decreased hemoglobin (less than 10 g/dL: up to 23%; less than 8.5 g/dL: up to 2%), decreased neutrophils (0.5 to less than 0.75 x 10[9]/L: up to 15%; less than 0.5 x 10[9]/L: up to 5%), and decreased platelets (25 to less than 50 x 10[9]/L: up to 1%) have been reported.Pancytopenia was reported, particularly in patients using concomitant pegylated interferon.[Ref]
Very common (10% or more): Decreased hemoglobin (up to 23%), anemia (up to 21%), neutropenia (up to 17%), decreased neutrophils (up to 15%), decreased lymphocyte count, decreased platelet countUncommon (0.1% to 1%): Pancytopenia[Ref]
Serious symptomatic bradycardia has been reported in patients taking amiodarone who started therapy with this drug in combination with another hepatitis C virus direct-acting antiviral.[Ref]
Postmarketing reports: Symptomatic bradycardia (including cases requiring pacemaker intervention)[Ref]
Very common (10% or more): Decreased appetite (up to 18%)Common (1% to 10%): Decreased weight[Ref]
Very common (10% or more): Myalgia (up to 14%), arthralgiaCommon (1% to 10%): Increased creatine kinase, back pain, muscle spasms[Ref]
Increased creatine kinase (at least 10 times ULN) was reported in up to 2% of patients.  Creatine kinase elevation was isolated and asymptomatic.[Ref]
Very common (10% or more): Dyspnea, coughCommon (1% to 10%): Nasopharyngitis, exertional dyspnea[Ref]
Common (1% to 10%): Increased total bilirubin[Ref]
Increased total bilirubin (greater than 1.5 times ULN) was reported in up to 3% of patients.  Bilirubin levels peaked during the first 1 to 2 weeks of therapy then decreased and returned to baseline levels by 4 weeks after therapy.  These bilirubin elevations were not associated with transaminase elevations.[Ref]
Common (1% to 10%): Blurred vision[Ref]
1. "Product Information. Sovaldi (sofosbuvir)." Gilead Sciences, Foster City, CA. 
2. Cerner Multum,  Inc. "Australian Product Information." O 0
3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0
4. FDA. U.S. Food and Drug Administration "FDA Drug Safety Communicaation: FDA warns of serious slowing of the heart rate when antiarrhythmic drug amiodarone is used with hepatitis C treatments containing sofosbuvir (Harvoni or Sovaldi) in combination with another Direct Acting Antiviral drug. Ava"   ([2015 Mar 24]):
It is possible that some side effects of sofosbuvir may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.

Chills
fever
lower back or side pain
pale skin
ulcers, sores, or white spots in the mouth
unusual tiredness or weakness


Changes in behavior
discouragement
feeling sad or empty
loss of interest or pleasure
thoughts of killing oneself
trouble concentrating


Chest pain or discomfort
lightheadedness, dizziness, or fainting
shortness of breath
slow or irregular heartbeat
unusual tiredness


Decreased appetite
diarrhea
difficulty with moving
headache
irritability
lack or loss of strength
muscle aching or cramping
muscle pains or stiffness
nausea
rash or itching skin
trouble sleeping

